NEWS

  • 2024/06/06 Correctseq

    CorrectSequence Therapeutics to Participate in EHA2024 Hybrid Congress

    June 6, 2024, CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical stage biotechnology company aims to use the innovative gene editing technology to help people with severe diseases, announ

    Details

  • 2024/06/03 Correctseq

    CorrectSequence Therapeutics to Participate in BIO International Convention 2024

    May 29, 2024, CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical stage biotechnology company aims to use the innovative gene editing technology to help people with severe diseases, announ

    Details

  • 2024/04/13 Correctseq

    CorrectSequence Therapeutics to Participate in the 27th Annual Meeting of American Society of Gene & Cell Therapy

    April 12, 2024, CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical stage biotechnology company aims to use the innovative gene editing technology to help people with severe diseases, anno

    Details

  • 2024/04/02 Correctseq

    CorrectSequence Therapeutics’ Base Editing Drug "CS-101 Injection" Obtains IND Approval from the NMPA

    CorrectSequence Therapeutics’ (Correctseq’s) base editing drug "CS-101 Injection" targeting transfusion-dependent β-thalassemia has obtained IND approval from the National Medical Products Administration (NMPA) of China on April 2, 2024 (acceptance number: CXSL2400021). This is the Chinese first base editing therapy with β-thalassemia. Correctseq is initiating the Phase 1 clinical study for CS-101 (clincialtrials.gov reference # NCT06291961).

    Details

  • 2024/01/16 Correctseq

    Jia Chen, Co-founder of CorrectSequence Therapeutics to Participate in the 5th International Conference on Base Editing, Prime Editing & Related Enzymes

    January 17-19, 2024, PST, the 5th International Conference on Base Editing, Prime Editing & Related Enzymes will be held at San Diego, California. Dr. Jia Chen, Professor of ShanghaiTech University, Co-founder of CorrectSequence Therapeutics will participate in this conference and give an oral presentation titled” Therapeutic base editing for β-thalassemia” on Jan. 17, at 5:05 - 5:20 pm, PST.

    Details

  • 2024/01/08 Crectseq

    The World’s First Clinical Base Editing Therapy for Hemoglobinopathy

    On January 8, 2024, Shanghai, China, CorrectSequence Therapeutics Co., Ltd. (Correctseq), using innovative transformer Base Editing (tBE) technology to help people with severe diseases, announced positive results of its base editing therapy for transfusion-dependent β-thalassemia, CS-101. As a collaboration with the First Affiliated Hospital of Guangxi Medical University, the Investigator-Initiated Trial (IIT) of CS-101 has successfully cured the first treated patient with transfusion-dependent β-thalassemia, resulting in sustained transfusion-free for more than two months.

    Details

  • 2023/11/24 Correctseq

    Cell Stem Cell | A novel strategy for treating β-hemoglobinopathy based on the transformer base editor (tBE)

    CorrectSequence Therapeutics (Correctseq), a biotechnology company using innovative base editing technology to help people with severe disease, today announced that the company and the research teams from ShanghaiTech University, Wuhan University, Fudan University and Children's Hospital of Fudan University published an article entitled “Base editing of the HBG promoter induces potent fetal hemoglobin expression with no detectable off-target mutations in human HSCs” in Cell Stem Cell on November 20th, 2023, reporting a novel base editing strategy for treating β-hemoglobinopathies with transformer base editor (tBE).

    Details

  • 2023/10/17 Correctseq

    CorrectSequence Therapeutics to Participate in the 18th ASCAT Conference

    CorrectSequence Therapeutics (Correctseq), a biotechnology company using innovative base editing technology to help people with severe disease, today announced that Dr. Susan Mou, CEO of Correctseq and Dr. Lijie Wang, head of Gene Editing Platform of Correctseq, will attend the 18th Academy for Sickle Cell and Thalassaemia Conference (ASCAT) at the County Hall London, UK on October 25-28, 2023. Dr. Lijie Wang, will give an oral presentation on Oct. 28, at 9:00 am - 11:15 am, local time.

    Details

上一页1234下一页 转至第
CorrectSequence Therapeutics Co., Ltd. © (2021-2022)
沪ICP备2020032248号
Powered by MetInfo 7.7 ©2008-2024  mituo.cn
HOME
ABOUT
NEWS
CONTACT